MULTICOMPONENT CRYSTALLINE SYSTEM COMPRISING NILOTINIB AND SELECTED CO-CRYSTAL FORMERS
    2.
    发明公开
    MULTICOMPONENT CRYSTALLINE SYSTEM COMPRISING NILOTINIB AND SELECTED CO-CRYSTAL FORMERS 审中-公开
    KRISTALLINES系统麻醉剂美沙酮KIMPONENTEN MIT NILOTINIB UNDAUSGEWÄHLTENCO-KRISTALL-FORMERN

    公开(公告)号:EP2909191A1

    公开(公告)日:2015-08-26

    申请号:EP13783008.9

    申请日:2013-10-16

    Applicant: BASF SE

    CPC classification number: C07D401/14

    Abstract: The present invention relates to crystalline materials comprising nilotinib and a carboxylic acid, carboxylic acid ester, carboxylic acid amide or sulfonic acid as a co-crystal former, and to pharmaceutical compositions comprising said materials. The invention also relates to processes for preparing said crystalline materials and to methods of using said crystalline materials to treat a disease condition in which tyrosine kinase inhibition is beneficial.

    Abstract translation: 本发明涉及包含尼罗替尼和羧酸,羧酸酯,羧酸酰胺或磺酸作为共晶体形成剂的结晶材料以及包含所述材料的药物组合物。 本发明还涉及制备所述结晶材料的方法以及使用所述结晶材料治疗其中酪氨酸激酶抑制是有益的疾病状况的方法。

    PHOTO-LATENT TITANIUM CATALYSTS
    4.
    发明公开
    PHOTO-LATENT TITANIUM CATALYSTS 审中-公开
    FOTOLATENTE TITANKATALYSATOREN

    公开(公告)号:EP2477739A1

    公开(公告)日:2012-07-25

    申请号:EP10750127.2

    申请日:2010-09-09

    Applicant: BASF SE

    Abstract: The present invention provides a photolatent Ti-chelate catalyst formulation, comprising (i) at least one compound of the formula (I) wherein R1 is C1-C20alkyl or C2-C20alkyl which is interrupted by one or more non-consecutive O-atoms; Y is formula (II) or optionally substituted phenyl; Y1 is formula (III) or optionally substituted phenyl; Y2 is formula (IV) or optionally substituted phenyl; Y3 is formula (V) or optionally substituted phenyl; R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13 independently of each other are hydrogen, halogen, optionally substituted C1-C20alkyl, or R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13 independently of each other are optionally substituted C6-C14aryl, provided that only one of R2, R3, R4 is hydrogen and only one of R5, R6, R7 is hydrogen and only one of R8, R9, R10 is hydrogen and only one of R11, R12, R13 is hydrogen; and (ii) at least one chelate ligand compound of the formula IIa, IIb or IIc, wherein Y′ is formula (VI) or formula (VII); Y′1 is formula (VIII) or formula (IX); R′2, R′3, R′4, R′5, R′6 and R′7 independently of each other have on of the meanings as given for R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13; and R′14, R′15 and R′16 independently of each other have on of the meanings as given for R14, R15 and R16.

    Abstract translation: 本发明提供了一种光催化剂钛螯合催化剂制剂,其包含(i)至少一种式(I)化合物,其中R 1为被一个或多个非连续O原子间隔的C 1 -C 20烷基或C 2 -C 20烷基; Y是式(II)或任选取代的苯基; Y1是式(III)或任选取代的苯基; Y2是式(IV)或任选取代的苯基; Y 3为式(Ⅴ)或任选取代的苯基; R2,R3,R4,R5,R6,R7,R8,R9,R10,R11,R12和R13彼此独立地是氢,卤素,任选取代的C 1 -C 20烷基,或者R 2,R 3,R 4,R 5,R 6,R 7 R 8,R 9,R 10,R 11,R 12和R 13彼此独立地是任选取代的C 6 -C 14芳基,条件是R 2,R 3,R 4中只有一个是氢,并且R 5,R 6,R 7中只有一个是氢, R8,R9,R10是氢,R11,R12,R13中只有一个是氢; 和(ii)至少一种式IIa,IIb或IIc的螯合配体化合物,其中Y'为式(VI)或式(VII); Y'1是式(VIII)或式(IX); R'2,R'3,R'4,R'5,R'6和R'7彼此独立地具有对R2,R3,R4,R5,R6,R7,R8,R9给出的含义 ,R10,R11,R12和R13; R 14,R'15和R 16彼此独立地具有对R 14,R 15和R 16给出的含义。

Patent Agency Ranking